EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Ekkehard Grünig, Pavel Jansa, Fenling Fan, Jakob A Hauser, Matthieu Pannaux, Adele Morganti, Hany Rofael, Kelly M Chin

Journal of the American College of Cardiology · 2024-01 · 83 (4) · 473-484

DOI: 10.1016/j.jacc.2023.10.045 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2024-01. Verfasst von Ekkehard Grünig und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thoraxklinik at Heidelberg University Hospital and Translational Lung Research Center, German Center for Lung Research, Heidelberg, Germany. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients. A fixed-dose combination of the ERA macitentan and PDE5i tadalafil (M/T FDC) in a once-daily, single tablet would simplify treatment. OBJECTIVES: The multicenter, double-blind, adaptive phase 3 A DUE study investigated the efficacy and safety of M/T FDC vs macitentan 10 mg and vs tadalafil 40 mg monotherapies in PAH patients, including treatment-naïve and prior ERA or PDE5i monotherapy-treated patients. METHODS: World Health Organization functional class II-III patients were randomized to M/T FDC, macitentan, or tadalafil depending on their PAH treatment (treatment-naïve, ERA, or PDE5i monotherapy) at baseline. The primary endpoint was change in pulmonary vascular resistance (PVR) at week 16. RESULTS: In total, 187 patients were randomized to single-tablet M/T FDC (n = 108), macitentan (n = 35), or tadalafil (n = 44). PVR reduction with M/T FDC was significantly greater vs macitentan (29%; geometric mean ratio 0.71; 95% CL: 0.61-0.82; P < 0.0001) and vs tadalafil (28%; geometric mean ratio 0.72; 95% CL: 0.64-0.80; P < 0.0001). Three patients died in the M/T FDC arm (judged unrelated to treatment). Adverse events (AEs) leading to discontinuation, serious AEs, and those of special interest (anemia, hypotension, and edema) were more frequent with M/T FDC. CONCLUSIONS: Macitentan and tadalafil FDC significantly improved PVR vs monotherapies in PAH patients, with a safety and tolerability profile consistent with the individual components. The A DUE study supports M/T FDC as a once-daily, single-tablet combination for initial therapy and escalation to double combination therapy in patients with PAH. (Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension [PAH]) [A DUE]; NCT03904693).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionPyrimidinesSulfonamidesHumansTadalafilCombined Modality TherapyPhosphodiesterase 5 InhibitorsEndothelin Receptor AntagonistsTablets

Stichwörter der Autor:innen

macitentanpulmonary arterial hypertensionrandomized controlled trialsingle-tablet (fixed-dose) combination therapytadalafil

Substanzen

TadalafilmacitentanPhosphodiesterase 5 InhibitorsEndothelin Receptor AntagonistsTabletsPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Thoraxklinik at Heidelberg University Hospital and Translational Lung Research Center, German Center for Lung Research, Heidelberg, Germany.
  • Charles University and General University Hospital, Prague, Czech Republic.
  • First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Clinical Science, Allschwil, Switzerland.
  • Cytel Inc, Cambridge, Massachusetts, USA.
  • Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Statistical Decision Science, Allschwil, Switzerland.

Zitieren

APA

Grünig, E., Jansa, P., Fan, F., Hauser, J. A., Pannaux, M., Morganti, A., Rofael, H., & Chin, K. M. (2024). Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 83(4), 473-484. https://doi.org/10.1016/j.jacc.2023.10.045

Vancouver

Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 2024;83(4):473-484. doi:10.1016/j.jacc.2023.10.045

BibTeX
@article{Grnig2024,
  author = {Grünig, Ekkehard and Jansa, Pavel and Fan, Fenling and Hauser, Jakob A and Pannaux, Matthieu and Morganti, Adele and Rofael, Hany and Chin, Kelly M},
  title = {Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension},
  journal = {Journal of the American College of Cardiology},
  year = {2024},
  volume = {83},
  number = {4},
  pages = {473--484},
  doi = {10.1016/j.jacc.2023.10.045}
}
Kostenlos starten →